Stem-Cell Cocktail Given Green Light

Italy’s outgoing health minister allows patients to receive an unproven stem cell cocktail at the government’s expense.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NISSIM BENVENISTYA combination of patient-derived stem cells, which have no publication record of efficacy, can now be given to children with incurable diseases in Italy. Disregarding the country’s health regulatory agency’s recommendations, the outgoing health minister Renato Balduzzi last week (March 21) announced that he would allow the use of the cell cocktail to a group of 32 terminally ill patients, mostly children, through a compassionate use program that makes the cells free to patients. Several days later, hundreds protested in Rome for even wider approval of the cells.

Psychologist Davide Vannoni, president of the Stamina Foundation, which produces the cells, developed the cocktail and tested it in Russia. Vannoni treated 80 patients, including people with Alzheimer’s, Parkinson’s, and muscle wasting disorders with the Stamina cocktail, but published none of the results or precise details of the therapy.

“That has been the underlying problem in the Stamina debacle,” Amedeo Santosuosso, a Milanese judge and a professor at the University of Pavia, told Nature. “In the case of the Stamina Foundation therapy, there is no suggestion that it might be efficacious, so in my opinion compassionate use is not legitimate.”

Scientists at the Italian Medicines Agency (AIFA) and other health institutes tried to shut down Stamina’s operations after a site visit determined that the facility ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies